Harlow campus plan puts UK biosecurity infrastructure on a single site
The UK Health Security Agency’s plan to consolidate critical laboratory and corporate functions at a new UK Health Security Campus in Harlow is now framed as a long-range response to an aging and fragmented national health security estate. The programme is designed to bring together specialist scientific facilities now split across Porton Down and Colindale, while also co-locating the agency’s headquarters with the new laboratory campus. For a public health system that depends on rapid pathogen detection, secure containment and uninterrupted scientific operations, the move is more than an estate reshuffle. It is an attempt to rebuild the physical backbone of national biosecurity.
A modern campus with CL2-CL4 laboratories sits at the center of the proposal, including the UK’s first suited CL4 facility for public health. That detail matters because the most dangerous infectious threats require the highest level of containment, and the capacity to work safely at that level is a strategic public asset rather than a routine capital project. By moving specialist functions into one integrated site, the programme aims to reduce duplication, improve operational resilience and give scientists a campus built for current and future outbreak demands. The plan also places the site inside the London-Cambridge Innovation Corridor, a location chosen for access to one of the UK’s strongest life sciences labor markets.
The programme’s case rests on a straightforward clinical and operational logic: outdated infrastructure slows science, raises maintenance burden and exposes critical functions to avoidable disruption. In infectious disease preparedness, delays are rarely abstract. A laboratory network that can isolate, classify and analyze threats quickly is part of the country’s first line of defense, and a campus built for continuity may shorten the time between signal detection and public health action.
Governance, legality and public spending controls are central to the assessment
The accounting officer assessment places the programme within the UKHSA’s legal mandate to detect, assess and respond to public health threats. UKHSA is an executive agency of the Department of Health and Social Care, with statutory functions exercised on behalf of the Secretary of State under the National Health Service Act 2006, the Health and Social Care Act 2012 and the Civil Contingencies Act 2004. Spending for the programme falls within the department’s ambit, and the assessment states that decision-making will proceed in line with public law, the Civil Service Code and the Seven Principles of Public Life.
Commercial activity is expected to follow applicable procurement regulations, with oversight through UKHSA and DHSC investment committees. Existing financial controls, including transactional-level accounts payable review and budgetary control, are intended to monitor expenditure and reduce fraud and error risk. The governance structure is layered: a Programme Board reports to the UKHSA Executive Committee, while expert groups such as the UKHSC Oversight Group, the UKHSA Advisory Board, the Science and Research Committee and the DHSC Portfolio Oversight Board provide additional scrutiny. The assessment concludes that the regularity test has been satisfied.
One sentence captures the compliance position plainly: the programme is being treated as a major public investment that must remain auditable from procurement to delivery.
Propriety controls are also built into the design. The integrated assurance and approvals plan sets out the sequence for assurance, escalation and decision-making across the programme lifecycle, with external scrutiny from HM Treasury spending controls, Cabinet Office requirements and gateway reviews under the Government Major Projects Portfolio and the National Infrastructure and Service Transformation Authority. In March 2026, a gateway review assigned an amber delivery confidence assessment and issued recommendations on board transition, decision rights and membership. Those recommendations have been acted on as the programme has moved into delivery.
Harlow Central is the only option that met all strategic objectives
Four options were reviewed in the most recent appraisal: Business As Usual, Harlow Do Minimum, Harlow Central and Harlow Advanced. Harlow Central emerged as the only option that met all strategic objectives while staying within the £3.52 billion envelope. It was the preferred option because it combines modern high-containment capacity with operational consolidation and a more durable long-term estate model.
The economic case is driven by several linked effects. Faster outbreak response, reduced CL4 downtime, improved laboratory productivity and better internal collaboration from co-location all contribute to the risk-adjusted Net Present Social Value of £6.70 billion and a Benefit-Cost Ratio of 4.77 compared with business as usual. Those benefits remained resilient across sensitivity analyses that tested lower productivity gains and smaller improvements in vaccine rollout. In other words, the programme’s economic argument does not depend on a single optimistic assumption holding perfectly in place.
A second line of value comes from the estate itself. Sixty-year post-investment whole-life cost modelling supports long-term revenue financial sustainability through reduced duplication, estate consolidation and lower running costs than the current arrangement. The assessment also states that the preferred option delivers value for money over 10- and 25-year horizons, which is important because high-containment facilities become expensive not only when they are built, but when they are kept safe, functional and compliant over decades.
Workforce transition is the largest practical challenge in the delivery plan
Feasibility hinges on whether the programme can move not just buildings, but people. Around 2,500 staff across Porton Down, Colindale and the London headquarters will need to relocate or transition as consolidation proceeds in the 2030s. That scale of movement creates a workforce challenge unlike a conventional capital build. Scientific continuity depends on retaining specialist knowledge, preserving laboratory routines and avoiding loss of institutional memory during transfer.
The business case therefore includes a multi-year people transition strategy covering retention, recruitment, training, dual-running arrangements, knowledge transfer, relocation support and workforce planning. An embedded team of HR specialists is already part of the programme, but the assessment is explicit that more work will be needed as delivery advances. Benchmarking against comparable public and private programmes has informed the planning approach, and the assessment makes clear that relocation is only one lever among several workforce management tools.
Programme completion is scheduled for September 2038, with 12 months of contingency built into design and construction. Capability is being rebuilt around the programme through an integrated delivery organisation with commercial, financial, technical, scientific and PMO expertise, alongside plans to procure a multi-year delivery partner and other specialist advisers. The market for high-containment laboratory construction is limited, and that scarcity raises the stakes for sequencing, procurement timing and supplier coordination.
The practical question now is whether a programme of this size can hold together long enough to deliver the scientific estate the UK says it needs. The assessment accepts the delivery challenge, but the staffing transition, specialist market constraints and long construction horizon leave little room for slippage if the campus is to arrive on time and with the promised biosecurity capability intact.